硝酸甘油舌下粉剂与外周动脉疾病门诊安慰剂对照的随机概念验证研究
这项多中心、随机、双盲、安慰剂对照、强制滴定IIa期概念验证研究纳入73例外周动脉疾病Fontaine IIb期患者,评估间歇舌下硝酸甘油粉剂对步行距离的影响。12周时,硝酸甘油组较基线经安慰剂校正的初始跛行距离增加23.2%(p=.35),绝对跛行距离增加3.6%(p=.44),均未达统计学显著。停药后第26周仍见ICD增加49.3%(p=.31)和ACD增加20.6%(p=.21),药物耐受良好,提示潜在即刻与持续效应,但需进一步研究。
要点
- 12周时ICD安慰剂校正增加23.2%、ACD增加3.6%,均无统计学显著性。
- 停药后第26周仍见ICD增加49.3%、ACD增加20.6%,但同样不显著。
- 硝酸甘油舌下粉剂耐受良好,但IIa期概念验证未达主要终点。
核心结论
- 间歇舌下硝酸甘油粉剂可能成为Fontaine IIb期PAD的潜在治疗选择,具即刻和持续效应。
- 但本IIa期概念验证研究中ACD和ICD的增加无统计学显著性,需进一步研究。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照、强制滴定IIa期概念验证研究。
- 筛查95例,随机73例,完成12周治疗期53例(硝酸甘油26例,安慰剂27例)。
- 基线、12周治疗及第19、26周(无治疗)行平板运动试验。
主要发现
- 基线ICD为硝酸甘油组59.2±32.8 m、安慰剂组57.5±39.7 m,12周硝酸甘油组安慰剂校正ICD较基线增加23.2%(p=.35)。
- 基线ACD为硝酸甘油组105.3±52.9 m、安慰剂组106.1±95.0 m,12周安慰剂校正ACD增加3.6%(p=.44),个体间变异大。
- 基线ICD≥50 m者ΔICD 29.3%(p=.19),基线ACD≥100 m者ΔACD 8.5%(p=.40)。
- 第26周ICD增加49.3%(p=.31)、ACD增加20.6%(p=.21),提示效应持续至治疗期后。
- 硝酸甘油舌下粉剂耐受良好。
临床怎么用
- 目前证据尚不支持常规处方间歇舌下硝酸甘油粉剂治疗Fontaine IIb期PAD。
- 对基线ICD≥50 m或ACD≥100 m的患者可能效应更明显,但需进一步验证。
局限性
- IIa期概念验证研究,样本量小,主要终点未达统计学显著性。
- 个体间变异大,结果解释需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treatment of peripheral artery disease (PAD), Fontaine Stage IIb with vasoactive substances is of limited efficacy and does not last beyond the active treatment. Glyceryl trinitrate (GTN) is a vasodilating agent that relaxes vascular smooth muscle cells. The aim was to prove the concept that GTN sublingual powder has sustained clinical efficacy and adequate safety in these patients. METHODS: This was a multicentre, randomised, double blind, placebo controlled, forced titration, proof of concept study (phase IIa). Patients had a treadmill test at baseline, after 12 weeks of GTN/placebo administration, and at 19 and 26 weeks (without treatment). Primary objectives were an increase in initial claudication distance (ICD) and absolute claudication distance (ACD) at 12 weeks. RESULTS: Ninety-five patients were screened and 73 randomised, of which 53 patients completed the 12 week treatment phase (GTN 26, placebo 27). At a baseline ICD of 59.2 ± 32.8 m (GTN) and 57.5 ± 39.7 m (placebo), GTN led to a placebo corrected ICD increase of 23.2% vs. baseline (p = .35). Baseline ACD was 105.3 ± 52.9 m (GTN) and 106.1 ± 95.0 m (placebo), and GTN led to a placebo corrected increase of 3.6% (p = .44), with substantial interindividual variation. The change in claudication distance was greater in patients with an ICD of ≥50 m at baseline (ΔICD 29.3%; p = .19), and an ACD ≥ 100 m (ΔACD 8.5%; p = .40). The effect lasted beyond the active treatment period as shown by a 49.3% increase in ICD (p = .31) and a 20.6% increase in ACD (p = .21) by week 26. GTN sublingual powder was well tolerated. CONCLUSION: Intermittent treatment with nitroglycerin sublingual powder may represent a potential treatment option for patients with PAD stage Fontaine IIb, with an immediate and a sustained effect. The observed increases in ACD and ICD were however not statistically significant in this phase IIa proof of concept study. Further studies are required.
引用
- Lawall H, Bramlage P, Gorath M, et al. Intermittent Administration of Nitroglycerin Sublingual Powder Compared with Placebo in Outpatients with Peripheral Artery Disease: Results of a Randomised Proof of Concept Study. Eur J Vasc Endovasc Surg. 2020. PMID: 33358350. doi:10.1016/j.ejvs.2020.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。